Cassava Sciences Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Vanguard Information Technology Index Fund ETF trades at $121.79. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VGT | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | — |
52-Week High | $4.64 | $125.77 |
52-Week Low | $0.87 | $83.59 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
VGT trades at $121.35, up 0.91% today, with a bullish technical outlook supported by moving averages but neutral oscillators. The ETF's pure-play technology focus, driven by AI infrastructure exposure, has attracted significant institutional buying, as seen in recent SEC filings. Recent news highlights strong performance relative to broader tech ETFs, with key holdings like Microsoft and Nvidia fueling gains.
Outlook remains positive due to AI-driven capital expenditure trends, though concentration risk in top holdings and potential sector volatility pose challenges. The ETF's low-cost structure and momentum position it for continued growth, but investors should monitor semiconductor cyclicality and broader market sentiment.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →